Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/...
20 Novembre 2018 - 5:45PM
PRESS RELEASE · PRESS RELEASE · PRESS
RELEASE
Neovacs announces the patent
filing in Europe and in the United States for its new therapeutic
vaccine candidate Kinoid IL-4/IL-13
for the treatment
of allergies
Paris and Boston,
November 20th 2018 - 17h45
CET (Euronext Growth Paris: ALNEV), leader in active
immunotherapy for the treatment of autoimmune and inflammatory
diseases, announces patent filing after having achieved preclinical
proof of concept with its new vaccine IL-4/IL-13 Kinoid for the
treatment of asthma.
The allergy model used is based on
the works of Sibilano[1] because it
expresses the principal asthma symptoms in humans, being an
inflammation and a hyper reactivity of the respiratory tract. In
this asthma model using sensitivity to mite dust, the immunization
with IL-4/IL-13 Kinoid induces a strong production of antibodies
neutralizing both cytokines and reducing the major symptoms of
asthma.
This result enables the filing of
a patent for this new Kinoid which targets the two cytokines key to
the development of allergies of all types, whether respiratory,
dermatologic or alimentary. Neovacs will now move forward with the
preclinical development necessary to conduct clinical trials in
these pathologies.
Neovacs announced in July 2018 the
results of its Phase IIb trial with IFNalpha Kinoid for the
treatment of Lupus which validated the innovative therapeutic
approach in humans and the move into Phase III.
In parallel the company continues
its ongoing preclinical development in type 1 diabetes with
IFNalpha Kinoid.
About
Allergies
Allergies are a major public
health problem whose prevalence is steadily increasing, affecting
globally 300 million people suffer from asthma and about 200 to 250
million people suffer from food allergies. One tenth of the
population suffers from drug allergies and 400 million from
rhinitis[2]. To date,
there is no effective treatment over time for these diseases. The
cytokines IL-4 and IL-13 play a key role in allergic reactions and
therefore represent major therapeutic targets. Most current
treatments for allergies are symptomatic (mainly antihistamines and
corticosteroids). The only therapeutic strategy developed to date
is allergen-specific immunotherapy, which consists of administering
increasing doses of an allergen over several months for
desensitization. However, allergen-specific immunotherapy is
limited by high levels of biomedical adverse reactions and poor
long-term efficacy, particularly for food allergies.
About
Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary
technology for inducing a polyclonal immune response (covered by
four patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha Kinoid, an
immunotherapy being developed for the indication of lupus,
dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other
therapeutic vaccines in the fields of auto-immune diseases,
oncology and allergies. The goal of the Kinoid approach is to
enable patients to have access to safe treatments with efficacy
that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS -
Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
NEWCAP-
Media
Annie-Florence Loyer
+33 1 44 71 00 12 / + 33 6 88 20 35 59
afloyer@newcap.fr
Léa Jacquin
+33 1 44 71 20 41 / +33 6 58 14 84 66
ljacquin@newcap.fr
ORPHEON FINANCE -
Financial Communication and Investor Relations
James Palmer
+33 7 60 92 77 74
j.palmer@orpheonfinance.com
[1] Sibilano:
Nature Communication 2016; DOI: 10.1038/ncomms13696
[2] Pawankar:
Allergic diseases and asthma: a global public health concern and a
call to action. World Allergy Organization Journal 2014 7:12.
Press release
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: NEOVACS via Globenewswire
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Neovacs (EU:ALNEV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024